This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG) (LASER-MAG)
The Efficacy of Photobiomodulation in the Treatment of Anti-MAG-Induced Peripheral Neuropathy: LASER-MAG Study.
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.
The treatment of neuropathic pain is complex, but recently a new non-pharmacological therapy, photobiomodulation, has shown evidence of efficacy and improved quality of life in the treatment of these peripheral neuropathies.
This new therapy uses low-intensity lasers; it is non-invasive, athermic, and has no reported side effects. The general principle is to expose tissues to visible light in the red and near-infrared spectrum to elicit a biological response.
The study aims to evaluate the efficacy and tolerability of photobiomodulation in this population of patients with anti-MAG neuropathy.
研究概览
详细说明
研究类型
注册 (估计的)
联系人和位置
学习地点
-
-
-
Quimper、法国、29107
- Centre Hospitalier de Cornouaille
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- IgM gammopathy with the presence of anti-MAG antibodies
- symptomatic peripheral neuropathy
- patient agreement
Exclusion Criteria:
- Patients with a solid tumor located in areas exposed to PBM
- Patients under legal guardianship (guardianship, conservatorship...)
- cognitive disorders
- Peripheral neuropathy of other aetiologies
- Declining to participate
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
patients
patients with anti-MAG neuropathy due to IgM monoclonal gammopathy
|
Each patient receives 16 sessions of PBM over 6 weeks using the ATP38 device.
Both upper limbs are treated simultaneously for 12 minutes each.
The lower limbs are also treated for 12 minutes each.
Assessments of disability (ONLS, R-ODS), pain (NPSI), and quality of life (QLQ C30, QLQ CIPN20) are conducted weekly.
Neurological and hematological consultations are conducted before and after PBM sessions.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To evaluate the efficacy of photobiomodulation in the symptomatic treatment of anti-MAG-induced peripheral neuropathies
大体时间:From enrollment to the end of treatment at 3 months
|
Rasch-built Overall Disability Scale (R-ODS) score (0 to 48 = worse outcome)
|
From enrollment to the end of treatment at 3 months
|
|
To evaluate the efficacy of photobiomodulation in the symptomatic treatment of anti-MAG-induced peripheral neuropathies
大体时间:From enrollment to the end of treatment at 3 months
|
Overall Neuropathy Limitations Scale (ONLS) score (0-12=worse outcome)
|
From enrollment to the end of treatment at 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Improving the quality of life for patients with anti-MAG peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
|
EORTC QLQ-C30 score (28-112= worse outcome)
|
From enrollment to the end of treatment at 3 months
|
|
Improving the quality of life for patients with anti-MAG peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
|
EORTC QLQ-CIPN20 score (20 - 80 = worse outcome)
|
From enrollment to the end of treatment at 3 months
|
|
Stopping the progression of peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
|
Neuropathic Pain Symptom Inventory (NPSI) score.
Each question is rated on a scale from 0 to 10, where 0 means no pain at all and 10 means the worst pain.
|
From enrollment to the end of treatment at 3 months
|
|
motor response of peripheral neuropathy
大体时间:From enrollment to the end of treatment at 3 months
|
10-meter walk test
|
From enrollment to the end of treatment at 3 months
|
|
toxicity of PBM
大体时间:From enrollment to the end of treatment at 3 months
|
Neuropathic Pain Symptom Inventory (NPSI) score.
Each question is rated on a scale from 0 to 10, where 0 means no pain at all and 10 means the worst pain.
|
From enrollment to the end of treatment at 3 months
|
|
Efficacy of PBM in patient subgroups
大体时间:From enrollment to the end of treatment at 3 months
|
comparison of scores based on prior treatments received (anti-CD20 monoclonal antibody, polyvalent immunoglobulins, plasma exchange, corticosteroids)
|
From enrollment to the end of treatment at 3 months
|
合作者和调查者
调查人员
- 首席研究员:Le Clech LLC Lenaig, doctor、Centre Hospitalier de Cornouaille
出版物和有用的链接
一般刊物
- Argenta PA, Ballman KV, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DG, Winterhoff BJ, Rivard CL, Erickson BK. The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecol Oncol. 2017 Jan;144(1):159-166. doi: 10.1016/j.ygyno.2016.11.013. Epub 2016 Nov 22.
- Joy L, Jolien R, Marithe C, Stijn E, Laura S, Hilde L, Sandra B, Wendy N, Ruth H, Liesbeth R, Sylvana S, Sylvia H, Jeroen M. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial). Support Care Cancer. 2022 Jun;30(6):5509-5517. doi: 10.1007/s00520-022-06975-x. Epub 2022 Mar 21.
- Ebadi SA, Tabeie F, Tavakoli S, Khalili S. Effects of Photobiomodulation With Two Wavelengths of 630 and 810 nm on Diabetic Neuropathy. J Lasers Med Sci. 2023 Jul 25;14:e22. doi: 10.34172/jlms.2023.22. eCollection 2023.
- Jaccard A, Magy L, Arnulf B, Bridoux F, Roussel M. Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes. Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):385-392. doi: 10.1182/hematology.2025000728.
- Hanna R, Dalvi S, Bensadoun RJ, Raber-Durlacher JE, Benedicenti S. Role of Photobiomodulation Therapy in Neurological Primary Burning Mouth Syndrome. A Systematic Review and Meta-Analysis of Human Randomised Controlled Clinical Trials. Pharmaceutics. 2021 Nov 2;13(11):1838. doi: 10.3390/pharmaceutics13111838.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- LASER-MAG
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.